Brief: OSE Immunotherapeutics Presents Clinical And Preclinical Data From Its Immuno-Oncology Portfolio

Ose Immunotherapeutics SA

18/04/2023 06:31

April 18 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS PRESENTS CLINICAL AND PRECLINICAL
DATA
FROM ITS IMMUNO-ONCOLOGY PORTFOLIO
    * BI 765063, FIRST-IN-CLASS SIRPΑ INHIBITOR ON THE
SIRPΑ/CD47
MYELOID PATHWAY IN ADVANCED SOLID TUMORS
    * OSE-127, MONOCLONAL IMMUNOMODULATORY ANTIBODY TARGETING
CD127
RECEPTOR, ALPHA CHAIN OF INTERLEUKIN-7 RECEPTOR (IL-7R) IN ACUTE
LYMPHOBLASTIC LEUKEMIA
    * BICKI(®)-IL-7, BIFUNCTIONAL THERAPY TARGETING PD1 AND IL-7
TO
SUSTAIN EXHAUSTED T CELL FUNCTION AND TO DISARM TREG SUPPRESSIVE
ACTIVITY
    * IN ADDITION, PRECLINICAL CHARACTERIZATION DATA ON CLEC-1
(NEW
MYELOID IMMUNE CHECKPOINT) BINDING MECHANISM WILL ALSO BE
PRESENTED ON APRIL 19

Source text for Eikon:  ID:nBw5N4vS0a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))